The Recall Desk

State

Rhode Island product recalls

73,833 recalls have nationwide distribution and so reach Rhode Island. 3,054 additional recalls listed Rhode Island specifically in their distribution scope.

What the numbers show

Total
3,054
Critical
221
Severe
708
Most recent
2026-11-04

Of the 3,054 recalls naming Rhode Island we have scored against our rubric, 221 (7%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 708 (23%) are Severe.

These figures cover only the 3,054 recalls whose distribution notice names Rhode Island specifically. The 73,833 nationwide recalls listed below reach every state, so counting them here would make every state page show the same numbers.

56351–56375 of 76887

  • SevereFDA (Drugs)·D-681-2015·2015-04-29

    Attix Pharmaceuticals Recalls Flunarizine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Flunarizine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Flunarizine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereUSDA FSIS·071-2015·2015-04-29

    Golden Krust Patties Recalls Beef and Chicken Products for Undeclared Egg

    Golden Krust Patties is recalling approximately 9 million pounds of beef and chicken products because they contain egg, a known allergen, that is not declared on the label.

    Product
    Golden Krust Patties Inc. — Golden Krust Patties Recalls Beef and Chicken Products Due To Misbranding and Undeclared Allergens
    Category
    Food
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-924-2015·2015-04-29

    Attix Pharmaceuticals Recalls Tetracycline HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Tetracycline HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Tetracycline HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-646-2015·2015-04-29

    Attix Pharmaceuticals Recalls Duloxetine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Duloxetine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Duloxetine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-662-2015·2015-04-29

    Attix Pharmaceuticals Recalls Ethopropazine HCI Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Ethopropazine HCI active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Ethopropazine HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-495-2015·2015-04-29

    Attix Pharmaceuticals Recalls DMPS API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling 2,3-Dimercaptopropanesulfonic Acid Sodium Salt (DMPS) active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    2,3-Dimercaptopropanesulfonic Acid Sodium Salt (DMPS) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-510-2015·2015-04-29

    Attix Pharmaceuticals Recalls Ambroxol HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Ambroxol HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Ambroxol HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-720-2015·2015-04-29

    Attix Pharmaceuticals Recalls Hydroxocobalamin HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Hydroxocobalamin HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Hydroxocobalamin HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-759-2015·2015-04-29

    Attix Pharmaceuticals Recalls Levomefolate Calcium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Levomefolate Calcium API due to potential penicillin cross-contamination from inadequate facility separation. The recall affects lots distributed nationwide to compounding pharmacies and research organizations.

    Product
    Levomefolate Calcium or L-5-Methyltetrahydrofolate Calcium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-553-2015·2015-04-29

    Attix Pharmaceuticals Recalls Bupropion HCI Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Bupropion HCI active pharmaceutical ingredient due to potential penicillin cross-contamination from repackaging in a shared facility.

    Product
    Bupropion HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-733-2015·2015-04-29

    Attix Pharmaceuticals Recalls Indomethacin Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Indomethacin Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Indomethacin Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-687-2015·2015-04-29

    Attix Pharmaceuticals Recalls Fluprostenol Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Fluprostenol active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Fluprostenol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-748-2015·2015-04-29

    Attix Pharmaceuticals Recalls Lansoprazole Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of lansoprazole active pharmaceutical ingredient distributed between January 5, 2012, and February 12, 2015, due to potential penicillin cross-contamination.

    Product
    Lansoprazole active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-494-2015·2015-04-29

    Attix Pharmaceuticals Recalls 3,4-Diaminopyridine Due to Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling 3,4-Diaminopyridine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    3,4-Diaminopyridine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-621-2015·2015-04-29

    Attix Pharmaceuticals Recalls Desonide API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Desonide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Desonide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-739-2015·2015-04-29

    Attix Pharmaceuticals Recalls Itraconazole Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling itraconazole active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Itraconazole active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-547-2015·2015-04-29

    Attix Pharmaceuticals Recalls Bromfenac Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Bromfenac Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Bromfenac Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-928-2015·2015-04-29

    Attix Pharmaceuticals Recalls Thyroid Porcine Ingredient Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Thyroid Porcine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Thyroid Porcine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-932-2015·2015-04-29

    Attix Pharmaceuticals Recalls Tobramycin Base Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Tobramycin Base distributed between January 2012 and February 2015 due to potential penicillin cross-contamination during repackaging.

    Product
    Tobramycin Base active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-898-2015·2015-04-29

    Attix Pharmaceuticals Recalls Sodium Gluconate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Sodium Gluconate active pharmaceutical ingredient due to potential penicillin cross-contamination from repackaging in a shared facility.

    Product
    Sodium Gluconate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-525-2015·2015-04-29

    Artesunate API Recalled for Potential Penicillin Cross-Contamination

    Attix Pharmaceuticals is recalling Artesunate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Artesunate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-855-2015·2015-04-29

    Prednisolone Acetate Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Prednisolone Acetate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Prednisolone Acetate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-915-2015·2015-04-29

    Attix Pharmaceuticals Recalls Taurolidine Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of taurolidine active pharmaceutical ingredient distributed between January 2012 and February 2015 due to potential penicillin cross-contamination.

    Product
    Taurolidine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-829-2015·2015-04-29

    Attix Pharmaceuticals Recalls Paclitaxel API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Paclitaxel Semi-Synthetic active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Paclitaxel Semi-Synthetic active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-645-2015·2015-04-29

    Attix Pharmaceuticals Recalls Droperidol API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Droperidol active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Droperidol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide